Zenith Health Care Ltd

Zenith Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 April 2026, reflecting a nuanced improvement in its technical outlook and valuation metrics despite ongoing fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, signalling a cautious but more favourable stance among analysts.

Zenith Health Care Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, raising questions about its price attractiveness amid a deteriorating financial profile and a challenging market backdrop. The company’s price-to-earnings (P/E) ratio has surged to 39.77, pushing its valuation grade from fair to expensive, while its price-to-book value (P/BV) stands at 2.38, signalling a premium compared to historical and peer averages.

For the fifth consecutive session, Zenith Health Care Ltd has closed lower, hitting a fresh 52-week low of Rs 2.23 on 30 Mar 2026. This marks a steep decline of 21.85% over the last three days alone, underscoring persistent selling pressure despite pockets of positive financial data.

Zenith Health Care Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. Despite a recent 5.66% intraday price gain, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside deteriorating profitability metrics, raise questions about its price attractiveness relative to peers and historical benchmarks.

Zenith Health Care Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.2.5 today, marking a significant decline amid ongoing market pressures and company-specific factors. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial and technical performance.

Zenith Health Care Ltd, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.2.82 today, marking a significant decline in its stock price amid broader market weakness and company-specific financial concerns.

Zenith Health Care Ltd’s stock has declined to a fresh 52-week low of Rs.3.01, marking a significant downturn in its market performance amid broader sector and market pressures.

Zenith Health Care Ltd’s share price declined sharply to a new 52-week low of Rs.3.02 on 2 Mar 2026, marking a significant downturn amid broader market fluctuations and company-specific performance concerns.

Zenith Health Care Ltd’s valuation metrics have shifted notably, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving the stock into an expensive category relative to its historical averages and peer group. Despite a stagnant share price and underwhelming returns compared to the Sensex, the company’s deteriorating financial performance and valuation upgrade to ‘expensive’ raise questions about its price attractiveness for investors.

Zenith Health Care Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, marks a significant development for investors assessing the pharmaceutical and biotechnology sector’s micro-cap landscape.

Zenith Health Care Ltd has seen a marked shift in its valuation parameters, moving from a risky to an expensive rating, reflecting a significant change in price attractiveness. Despite a modest day gain of 0.60%, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios, when compared to historical averages and peer benchmarks, suggest caution for investors amid deteriorating fundamentals and a challenging sector backdrop.

Zenith Healthcare Limited posted a net profit of ₹0.22 crores in Q3 FY26, marking a sequential improvement of 57.14% from Q2 FY26's ₹0.14 crores, though the micro-cap pharmaceutical manufacturer continues to grapple with structural challenges that have plagued its financial performance for years. The Ahmedabad-based company, with a modest market capitalisation of ₹18.00 crores, reported revenue of ₹2.48 crores for the quarter, representing a 9.25% sequential uptick but only a modest 7.36% year-on-year gain. Despite the quarterly profit surge reaching its highest level in recent quarters, the stock has languished, trading at ₹3.36—down 34.76% over the past year and hovering just 10.16% above its 52-week low of ₹3.05.

Zenith Health Care Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 February 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Zenith Health Care, a player in the Pharmaceuticals & Biotechnology sector, touched a fresh 52-week low of Rs.3.05 today, marking a significant milestone in its ongoing price decline. The stock has been under pressure for several sessions, reflecting a challenging period for the company amid broader market fluctuations.